Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HPGDS | O60760 | 2/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14190101 | 0.86 | HPGDS (0.59) | NPC1RAB9ARXFP1HPGDSPTPN1 | |
| SCHEMBL14355078 | 0.86 | GRM5 (0.53) | NPC1RAB9AHPGDSGRM5 | |
| SCHEMBL2073316 | 0.85 | HPGDS (0.58) | NPC1RAB9ARXFP1HPGDSPTPN1 | |
| SCHEMBL1543648 | 0.84 | HPGDS (0.71) | NPC1RAB9AHPGDSGRM5 | |
| SCHEMBL28702883 | 0.82 | NPC1 (1.00) | NPC1RAB9AHTR2BPOLBGRM5 | |
| SCHEMBL2072683 | 0.81 | HPGDS (0.83) | HPGDS | |
| SCHEMBL3634670 | 0.81 | NPC1 (0.50) | NPC1RAB9AHPGDSPTPN1PTPN11 | |
| SCHEMBL2070758 | 0.79 | HPGDS (0.54) | HPGDS | |
| SCHEMBL2070563 | 0.79 | SIGMAR1 (0.74) | HPGDS | |
| SCHEMBL1543340 | 0.79 | HPGDS (0.74) | HPGDSGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307377-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| WO-2009153720-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009153720-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173888-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | NPC1 236/4885RAB9A 2122/4885RXFP1 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.